New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug ...
(RTTNews) - Novocure (NVCR) announced the FDA approved new Head Flexible Electrode transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme. Novocure ...
The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...
(RTTNews) - Novocure (NVCR) an oncology company, has received approval from the FDA for its new Head Flexible Electrode transducer arrays, designed for use with its Optune Gio device, which is used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results